Aberdeen Group plc Purchases 294,792 Shares of Alphatec Holdings, Inc. $ATEC

Aberdeen Group plc boosted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 29.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,286,195 shares of the medical technology company’s stock after purchasing an additional 294,792 shares during the quarter. Aberdeen Group plc owned about 0.87% of Alphatec worth $27,062,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Alphatec during the third quarter valued at about $34,000. Osterweis Capital Management Inc. acquired a new stake in shares of Alphatec in the 2nd quarter worth about $37,000. China Universal Asset Management Co. Ltd. bought a new position in Alphatec in the 3rd quarter valued at about $73,000. FNY Investment Advisers LLC bought a new position in Alphatec in the 3rd quarter valued at about $74,000. Finally, State of Alaska Department of Revenue acquired a new position in Alphatec during the 3rd quarter valued at about $120,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Price Performance

ATEC stock opened at $10.83 on Monday. The stock’s fifty day simple moving average is $13.05 and its two-hundred day simple moving average is $16.47. The company has a current ratio of 2.06, a quick ratio of 1.28 and a debt-to-equity ratio of 40.35. Alphatec Holdings, Inc. has a 1-year low of $8.81 and a 1-year high of $23.29. The stock has a market cap of $1.64 billion, a P/E ratio of -11.40 and a beta of 1.12.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $212.93 million during the quarter, compared to analysts’ expectations of $212.67 million. Alphatec’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) earnings per share. Analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling at Alphatec

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 88,835 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the transaction, the general counsel owned 559,459 shares in the company, valued at $6,987,642.91. This trade represents a 13.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the completion of the transaction, the chief operating officer owned 815,704 shares of the company’s stock, valued at $10,033,159.20. The trade was a 24.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 726,972 shares of company stock valued at $9,184,386 in the last three months. 20.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ATEC shares. Loop Capital set a $25.00 price objective on Alphatec in a research note on Wednesday, December 10th. Wells Fargo & Company upgraded Alphatec to a “strong-buy” rating in a report on Wednesday, March 18th. Lake Street Capital reissued a “buy” rating on shares of Alphatec in a research report on Wednesday, February 25th. Stifel Nicolaus dropped their price objective on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Finally, Barclays lifted their price objective on shares of Alphatec from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.82.

Alphatec Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.